Latest Announcements

Investor Announcement

Annual Report Filed on Form 20-F with SEC

Prana has announced that it has filed its Annual Report on Form 20-F


Investor Announcement, Parkinson's Disease

Prana commences research collaboration with Takeda for the treatment of Parkinson’s disease gastrointestinal neuropathology

PBT434, Prana’s lead drug in preclinical development for movement disorders, to be profiled in collaborative venture


Email Newsletter

Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"